Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today reported business highlights and financial results for the first quarter ended March 31, 2014.
“In the first quarter, we made significant progress in the development and advancement of all our programs,” said David Schenkein, M.D., chief executive officer of Agios.
Help employers find you! Check out all the jobs and post your resume.
